nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—TLR4—melanoma	0.512	0.804	CbGaD
Naloxone—ALB—melanoma	0.0639	0.1	CbGaD
Naloxone—ALB—Vemurafenib—melanoma	0.0611	0.397	CbGbCtD
Naloxone—ABCB1—melanoma	0.061	0.0958	CbGaD
Naloxone—CYP3A4—Temozolomide—melanoma	0.0349	0.227	CbGbCtD
Naloxone—ABCB1—Dactinomycin—melanoma	0.0212	0.138	CbGbCtD
Naloxone—CYP3A4—Vemurafenib—melanoma	0.0191	0.124	CbGbCtD
Naloxone—ABCB1—Docetaxel—melanoma	0.011	0.0712	CbGbCtD
Naloxone—CYP3A4—Docetaxel—melanoma	0.00657	0.0427	CbGbCtD
Naloxone—TLR4—eye—melanoma	0.00188	0.173	CbGeAlD
Naloxone—Grand mal convulsion—Carmustine—melanoma	0.00118	0.0459	CcSEcCtD
Naloxone—CREB1—neck—melanoma	0.00111	0.102	CbGeAlD
Naloxone—Encephalopathy—Carmustine—melanoma	0.000872	0.0341	CcSEcCtD
Naloxone—CREB1—eye—melanoma	0.000829	0.0761	CbGeAlD
Naloxone—CREB1—retina—melanoma	0.000822	0.0754	CbGeAlD
Naloxone—TLR4—lymph node—melanoma	0.000749	0.0687	CbGeAlD
Naloxone—CREB1—skin of body—melanoma	0.000721	0.0662	CbGeAlD
Naloxone—CREB1—mammalian vulva—melanoma	0.000658	0.0604	CbGeAlD
Naloxone—ESR1—blood vessel—melanoma	0.000613	0.0563	CbGeAlD
Naloxone—Injection site reaction—Carmustine—melanoma	0.000556	0.0217	CcSEcCtD
Naloxone—Coma—Carmustine—melanoma	0.000511	0.02	CcSEcCtD
Naloxone—Cardiac disorder—Vemurafenib—melanoma	0.000493	0.0193	CcSEcCtD
Naloxone—Angiopathy—Vemurafenib—melanoma	0.000482	0.0188	CcSEcCtD
Naloxone—Mediastinal disorder—Vemurafenib—melanoma	0.000479	0.0187	CcSEcCtD
Naloxone—Chills—Vemurafenib—melanoma	0.000477	0.0186	CcSEcCtD
Naloxone—CREB1—head—melanoma	0.000471	0.0432	CbGeAlD
Naloxone—Rhinorrhoea—Docetaxel—melanoma	0.000444	0.0173	CcSEcCtD
Naloxone—ESR1—neck—melanoma	0.000439	0.0403	CbGeAlD
Naloxone—Hot flush—Temozolomide—melanoma	0.00042	0.0164	CcSEcCtD
Naloxone—Menopausal symptoms—Temozolomide—melanoma	0.000416	0.0163	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000391	0.0153	CcSEcCtD
Naloxone—OPRD1—head—melanoma	0.000372	0.0342	CbGeAlD
Naloxone—Nervous system disorder—Vemurafenib—melanoma	0.00037	0.0145	CcSEcCtD
Naloxone—Skin disorder—Vemurafenib—melanoma	0.000367	0.0143	CcSEcCtD
Naloxone—Injection site reaction—Docetaxel—melanoma	0.000358	0.014	CcSEcCtD
Naloxone—OPRK1—head—melanoma	0.000357	0.0327	CbGeAlD
Naloxone—CREB1—lymph node—melanoma	0.00033	0.0303	CbGeAlD
Naloxone—Gastrointestinal disorder—Vemurafenib—melanoma	0.000326	0.0127	CcSEcCtD
Naloxone—Pulmonary oedema—Docetaxel—melanoma	0.00032	0.0125	CcSEcCtD
Naloxone—Depression—Carmustine—melanoma	0.000312	0.0122	CcSEcCtD
Naloxone—Depression—Temozolomide—melanoma	0.000302	0.0118	CcSEcCtD
Naloxone—Flushing—Bleomycin—melanoma	0.000299	0.0117	CcSEcCtD
Naloxone—Body temperature increased—Vemurafenib—melanoma	0.000298	0.0117	CcSEcCtD
Naloxone—Chills—Bleomycin—melanoma	0.000289	0.0113	CcSEcCtD
Naloxone—Hallucination—Carmustine—melanoma	0.00028	0.0109	CcSEcCtD
Naloxone—Hot flush—Docetaxel—melanoma	0.000279	0.0109	CcSEcCtD
Naloxone—Flushing—Dactinomycin—melanoma	0.000279	0.0109	CcSEcCtD
Naloxone—Menopausal symptoms—Docetaxel—melanoma	0.000277	0.0108	CcSEcCtD
Naloxone—Asthenia—Vemurafenib—melanoma	0.000271	0.0106	CcSEcCtD
Naloxone—Hallucination—Temozolomide—melanoma	0.00027	0.0106	CcSEcCtD
Naloxone—Chills—Dactinomycin—melanoma	0.000269	0.0105	CcSEcCtD
Naloxone—Flushing—Carmustine—melanoma	0.000261	0.0102	CcSEcCtD
Naloxone—Diarrhoea—Vemurafenib—melanoma	0.000258	0.0101	CcSEcCtD
Naloxone—OPRM1—head—melanoma	0.000254	0.0233	CbGeAlD
Naloxone—Flushing—Temozolomide—melanoma	0.000252	0.00985	CcSEcCtD
Naloxone—Cardiac disorder—Temozolomide—melanoma	0.000252	0.00985	CcSEcCtD
Naloxone—Angiopathy—Temozolomide—melanoma	0.000246	0.00962	CcSEcCtD
Naloxone—Mental disorder—Carmustine—melanoma	0.000246	0.00962	CcSEcCtD
Naloxone—Mediastinal disorder—Temozolomide—melanoma	0.000245	0.00956	CcSEcCtD
Naloxone—Chills—Temozolomide—melanoma	0.000244	0.00952	CcSEcCtD
Naloxone—ABCB1—blood vessel—melanoma	0.000242	0.0222	CbGeAlD
Naloxone—Vomiting—Vemurafenib—melanoma	0.00024	0.00938	CcSEcCtD
Naloxone—Mental disorder—Temozolomide—melanoma	0.000238	0.00929	CcSEcCtD
Naloxone—Nasopharyngitis—Docetaxel—melanoma	0.000233	0.00912	CcSEcCtD
Naloxone—Tremor—Carmustine—melanoma	0.000229	0.00895	CcSEcCtD
Naloxone—Agitation—Carmustine—melanoma	0.000225	0.00878	CcSEcCtD
Naloxone—Nausea—Vemurafenib—melanoma	0.000224	0.00876	CcSEcCtD
Naloxone—Tremor—Temozolomide—melanoma	0.000222	0.00865	CcSEcCtD
Naloxone—SLCO1A2—head—melanoma	0.000218	0.0201	CbGeAlD
Naloxone—Agitation—Temozolomide—melanoma	0.000217	0.00849	CcSEcCtD
Naloxone—Convulsion—Carmustine—melanoma	0.000212	0.00828	CcSEcCtD
Naloxone—Hypertension—Carmustine—melanoma	0.000211	0.00825	CcSEcCtD
Naloxone—Paraesthesia—Bleomycin—melanoma	0.000205	0.00802	CcSEcCtD
Naloxone—Convulsion—Temozolomide—melanoma	0.000205	0.008	CcSEcCtD
Naloxone—Hypertension—Temozolomide—melanoma	0.000204	0.00797	CcSEcCtD
Naloxone—Dyspnoea—Bleomycin—melanoma	0.000204	0.00797	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.0002	0.00781	CcSEcCtD
Naloxone—Pain—Bleomycin—melanoma	0.000196	0.00764	CcSEcCtD
Naloxone—Tachycardia—Carmustine—melanoma	0.000195	0.00761	CcSEcCtD
Naloxone—Nervous system disorder—Temozolomide—melanoma	0.000189	0.00739	CcSEcCtD
Naloxone—Skin disorder—Temozolomide—melanoma	0.000187	0.00732	CcSEcCtD
Naloxone—Hyperhidrosis—Temozolomide—melanoma	0.000187	0.00729	CcSEcCtD
Naloxone—ESR1—head—melanoma	0.000185	0.017	CbGeAlD
Naloxone—Pain—Dactinomycin—melanoma	0.000182	0.00713	CcSEcCtD
Naloxone—Body temperature increased—Bleomycin—melanoma	0.000181	0.00706	CcSEcCtD
Naloxone—Paraesthesia—Carmustine—melanoma	0.000179	0.007	CcSEcCtD
Naloxone—Dyspnoea—Carmustine—melanoma	0.000178	0.00695	CcSEcCtD
Naloxone—Paraesthesia—Temozolomide—melanoma	0.000173	0.00677	CcSEcCtD
Naloxone—Gastrointestinal disorder—Carmustine—melanoma	0.000172	0.00673	CcSEcCtD
Naloxone—Dyspnoea—Temozolomide—melanoma	0.000172	0.00672	CcSEcCtD
Naloxone—Pain—Carmustine—melanoma	0.000171	0.00667	CcSEcCtD
Naloxone—Body temperature increased—Dactinomycin—melanoma	0.000169	0.00659	CcSEcCtD
Naloxone—Abdominal pain—Dactinomycin—melanoma	0.000169	0.00659	CcSEcCtD
Naloxone—Cardiac disorder—Docetaxel—melanoma	0.000168	0.00655	CcSEcCtD
Naloxone—Flushing—Docetaxel—melanoma	0.000168	0.00655	CcSEcCtD
Naloxone—Gastrointestinal disorder—Temozolomide—melanoma	0.000167	0.00651	CcSEcCtD
Naloxone—Pain—Temozolomide—melanoma	0.000165	0.00644	CcSEcCtD
Naloxone—Asthenia—Bleomycin—melanoma	0.000164	0.00641	CcSEcCtD
Naloxone—Angiopathy—Docetaxel—melanoma	0.000164	0.0064	CcSEcCtD
Naloxone—Mediastinal disorder—Docetaxel—melanoma	0.000163	0.00636	CcSEcCtD
Naloxone—Chills—Docetaxel—melanoma	0.000162	0.00633	CcSEcCtD
Naloxone—Mental disorder—Docetaxel—melanoma	0.000158	0.00618	CcSEcCtD
Naloxone—Abdominal pain—Carmustine—melanoma	0.000158	0.00617	CcSEcCtD
Naloxone—Body temperature increased—Carmustine—melanoma	0.000158	0.00617	CcSEcCtD
Naloxone—Asthenia—Dactinomycin—melanoma	0.000153	0.00598	CcSEcCtD
Naloxone—Abdominal pain—Temozolomide—melanoma	0.000153	0.00596	CcSEcCtD
Naloxone—Body temperature increased—Temozolomide—melanoma	0.000153	0.00596	CcSEcCtD
Naloxone—ALB—lymph node—melanoma	0.000152	0.014	CbGeAlD
Naloxone—Diarrhoea—Dactinomycin—melanoma	0.000146	0.0057	CcSEcCtD
Naloxone—Vomiting—Bleomycin—melanoma	0.000145	0.00568	CcSEcCtD
Naloxone—Asthenia—Carmustine—melanoma	0.000143	0.0056	CcSEcCtD
Naloxone—Asthenia—Temozolomide—melanoma	0.000138	0.00541	CcSEcCtD
Naloxone—Diarrhoea—Carmustine—melanoma	0.000137	0.00534	CcSEcCtD
Naloxone—Convulsion—Docetaxel—melanoma	0.000136	0.00532	CcSEcCtD
Naloxone—Nausea—Bleomycin—melanoma	0.000136	0.00531	CcSEcCtD
Naloxone—Hypertension—Docetaxel—melanoma	0.000136	0.0053	CcSEcCtD
Naloxone—Vomiting—Dactinomycin—melanoma	0.000136	0.0053	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000133	0.00519	CcSEcCtD
Naloxone—Diarrhoea—Temozolomide—melanoma	0.000132	0.00516	CcSEcCtD
Naloxone—ESR1—lymph node—melanoma	0.00013	0.0119	CbGeAlD
Naloxone—ABCB1—retina—melanoma	0.000128	0.0117	CbGeAlD
Naloxone—Vomiting—Carmustine—melanoma	0.000127	0.00496	CcSEcCtD
Naloxone—Nausea—Dactinomycin—melanoma	0.000127	0.00495	CcSEcCtD
Naloxone—Nervous system disorder—Docetaxel—melanoma	0.000126	0.00492	CcSEcCtD
Naloxone—Tachycardia—Docetaxel—melanoma	0.000125	0.00489	CcSEcCtD
Naloxone—Skin disorder—Docetaxel—melanoma	0.000125	0.00487	CcSEcCtD
Naloxone—Vomiting—Temozolomide—melanoma	0.000123	0.00479	CcSEcCtD
Naloxone—Nausea—Carmustine—melanoma	0.000119	0.00463	CcSEcCtD
Naloxone—Paraesthesia—Docetaxel—melanoma	0.000115	0.0045	CcSEcCtD
Naloxone—Nausea—Temozolomide—melanoma	0.000115	0.00448	CcSEcCtD
Naloxone—Dyspnoea—Docetaxel—melanoma	0.000114	0.00447	CcSEcCtD
Naloxone—Gastrointestinal disorder—Docetaxel—melanoma	0.000111	0.00433	CcSEcCtD
Naloxone—Pain—Docetaxel—melanoma	0.00011	0.00429	CcSEcCtD
Naloxone—ABCB1—mammalian vulva—melanoma	0.000102	0.00939	CbGeAlD
Naloxone—Abdominal pain—Docetaxel—melanoma	0.000101	0.00396	CcSEcCtD
Naloxone—Body temperature increased—Docetaxel—melanoma	0.000101	0.00396	CcSEcCtD
Naloxone—Asthenia—Docetaxel—melanoma	9.21e-05	0.0036	CcSEcCtD
Naloxone—Diarrhoea—Docetaxel—melanoma	8.78e-05	0.00343	CcSEcCtD
Naloxone—Vomiting—Docetaxel—melanoma	8.16e-05	0.00319	CcSEcCtD
Naloxone—Nausea—Docetaxel—melanoma	7.62e-05	0.00298	CcSEcCtD
Naloxone—ABCB1—head—melanoma	7.32e-05	0.00672	CbGeAlD
Naloxone—ABCB1—lymph node—melanoma	5.12e-05	0.0047	CbGeAlD
Naloxone—OPRD1—Signaling Pathways—CXCL8—melanoma	3.55e-06	2.05e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HRAS—melanoma	3.54e-06	2.04e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGF—melanoma	3.53e-06	2.04e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HRAS—melanoma	3.53e-06	2.04e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GNAQ—melanoma	3.52e-06	2.04e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CD44—melanoma	3.52e-06	2.04e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—melanoma	3.51e-06	2.03e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—PIK3CA—melanoma	3.49e-06	2.02e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDKN1B—melanoma	3.48e-06	2.01e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDKN1B—melanoma	3.47e-06	2e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KDR—melanoma	3.44e-06	1.99e-05	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AKT1—melanoma	3.43e-06	1.98e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MAPK3—melanoma	3.42e-06	1.98e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.42e-06	1.98e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CASP3—melanoma	3.41e-06	1.97e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—melanoma	3.4e-06	1.97e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.4e-06	1.97e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CASP3—melanoma	3.4e-06	1.96e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—melanoma	3.39e-06	1.96e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—melanoma	3.39e-06	1.96e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP1B1—melanoma	3.38e-06	1.95e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—melanoma	3.37e-06	1.95e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—melanoma	3.37e-06	1.95e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—BRAF—melanoma	3.36e-06	1.94e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PIK3CA—melanoma	3.34e-06	1.93e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NRAS—melanoma	3.33e-06	1.93e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MDM2—melanoma	3.33e-06	1.92e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCND1—melanoma	3.32e-06	1.92e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FN1—melanoma	3.31e-06	1.91e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCND1—melanoma	3.31e-06	1.91e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CTNNB1—melanoma	3.28e-06	1.9e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB2—melanoma	3.28e-06	1.9e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CTNNB1—melanoma	3.27e-06	1.89e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1—melanoma	3.27e-06	1.89e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PLA2G6—melanoma	3.26e-06	1.88e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MAPK1—melanoma	3.25e-06	1.88e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—melanoma	3.25e-06	1.88e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOTCH1—melanoma	3.24e-06	1.87e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CB—melanoma	3.24e-06	1.87e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—HRAS—melanoma	3.23e-06	1.87e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PIK3CA—melanoma	3.23e-06	1.86e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—melanoma	3.22e-06	1.86e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—melanoma	3.21e-06	1.86e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDKN1A—melanoma	3.21e-06	1.85e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTEN—melanoma	3.2e-06	1.85e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDKN1A—melanoma	3.2e-06	1.85e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MAPK3—melanoma	3.19e-06	1.84e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTEN—melanoma	3.19e-06	1.84e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ABCB1—melanoma	3.19e-06	1.84e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NFKB1—melanoma	3.19e-06	1.84e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NFKB1—melanoma	3.18e-06	1.84e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ABCB1—melanoma	3.17e-06	1.83e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CD80—melanoma	3.17e-06	1.83e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CG—melanoma	3.17e-06	1.83e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APC—melanoma	3.17e-06	1.83e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KIT—melanoma	3.17e-06	1.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAP2K1—melanoma	3.16e-06	1.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CD—melanoma	3.14e-06	1.81e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGF—melanoma	3.13e-06	1.81e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AKT1—melanoma	3.12e-06	1.81e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AKT1—melanoma	3.11e-06	1.8e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—melanoma	3.11e-06	1.8e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PIK3CA—melanoma	3.11e-06	1.8e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTEN—melanoma	3.1e-06	1.79e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—melanoma	3.09e-06	1.79e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—melanoma	3.09e-06	1.79e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—melanoma	3.07e-06	1.78e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1B—melanoma	3.04e-06	1.76e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MAPK1—melanoma	3.04e-06	1.76e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FGF2—melanoma	3.01e-06	1.74e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AKT1—melanoma	3.01e-06	1.74e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—melanoma	2.98e-06	1.72e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP3—melanoma	2.98e-06	1.72e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—BRAF—melanoma	2.98e-06	1.72e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—melanoma	2.97e-06	1.72e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—melanoma	2.96e-06	1.71e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PRKCA—melanoma	2.94e-06	1.7e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—VCAN—melanoma	2.93e-06	1.69e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PRKCA—melanoma	2.92e-06	1.69e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ERCC2—melanoma	2.91e-06	1.68e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1—melanoma	2.9e-06	1.68e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—melanoma	2.9e-06	1.68e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ERCC2—melanoma	2.9e-06	1.67e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—melanoma	2.89e-06	1.67e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—melanoma	2.88e-06	1.67e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CTNNB1—melanoma	2.87e-06	1.66e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—melanoma	2.87e-06	1.66e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STAT3—melanoma	2.86e-06	1.65e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NRAS—melanoma	2.86e-06	1.65e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—melanoma	2.86e-06	1.65e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STAT3—melanoma	2.85e-06	1.65e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—AKT1—melanoma	2.85e-06	1.65e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NRAS—melanoma	2.85e-06	1.65e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PIK3CA—melanoma	2.82e-06	1.63e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—melanoma	2.81e-06	1.63e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MDM2—melanoma	2.81e-06	1.63e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1A—melanoma	2.8e-06	1.62e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAP2K1—melanoma	2.8e-06	1.62e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—melanoma	2.8e-06	1.62e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NFKB1—melanoma	2.78e-06	1.61e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CD—melanoma	2.78e-06	1.61e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—melanoma	2.77e-06	1.6e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MAPK3—melanoma	2.76e-06	1.59e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CB—melanoma	2.74e-06	1.58e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK3—melanoma	2.74e-06	1.58e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AKT1—melanoma	2.73e-06	1.58e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK3—melanoma	2.73e-06	1.58e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—melanoma	2.68e-06	1.55e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGF2—melanoma	2.67e-06	1.54e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—melanoma	2.66e-06	1.54e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—melanoma	2.65e-06	1.53e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CA—melanoma	2.63e-06	1.52e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—AKT1—melanoma	2.63e-06	1.52e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—melanoma	2.63e-06	1.52e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—melanoma	2.61e-06	1.51e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK1—melanoma	2.6e-06	1.5e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—melanoma	2.6e-06	1.5e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK1—melanoma	2.59e-06	1.5e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—melanoma	2.59e-06	1.5e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1B—melanoma	2.57e-06	1.48e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PRKCA—melanoma	2.56e-06	1.48e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—melanoma	2.55e-06	1.47e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AKT1—melanoma	2.54e-06	1.47e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ERCC2—melanoma	2.54e-06	1.47e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—melanoma	2.53e-06	1.46e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP3—melanoma	2.52e-06	1.46e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—melanoma	2.51e-06	1.45e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STAT3—melanoma	2.5e-06	1.45e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—melanoma	2.5e-06	1.45e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NRAS—melanoma	2.5e-06	1.44e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MDM2—melanoma	2.49e-06	1.44e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP17A1—melanoma	2.47e-06	1.43e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—melanoma	2.46e-06	1.42e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—melanoma	2.46e-06	1.42e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—melanoma	2.45e-06	1.42e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—melanoma	2.45e-06	1.42e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—melanoma	2.44e-06	1.41e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CB—melanoma	2.43e-06	1.4e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CTNNB1—melanoma	2.43e-06	1.4e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.41e-06	1.39e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.4e-06	1.39e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK3—melanoma	2.39e-06	1.38e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—melanoma	2.38e-06	1.38e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1A—melanoma	2.37e-06	1.37e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—melanoma	2.36e-06	1.37e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NFKB1—melanoma	2.35e-06	1.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GNA11—melanoma	2.33e-06	1.35e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—melanoma	2.33e-06	1.35e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—melanoma	2.33e-06	1.34e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AKT1—melanoma	2.31e-06	1.33e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CG—melanoma	2.3e-06	1.33e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CG—melanoma	2.29e-06	1.32e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—FASN—melanoma	2.28e-06	1.32e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1B—melanoma	2.28e-06	1.32e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK1—melanoma	2.27e-06	1.31e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—melanoma	2.27e-06	1.31e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CA—melanoma	2.26e-06	1.31e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CA—melanoma	2.25e-06	1.3e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC5A5—melanoma	2.25e-06	1.3e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP3—melanoma	2.23e-06	1.29e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—melanoma	2.23e-06	1.29e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARG—melanoma	2.22e-06	1.28e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARG—melanoma	2.21e-06	1.28e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CA—melanoma	2.19e-06	1.26e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—melanoma	2.18e-06	1.26e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—melanoma	2.18e-06	1.26e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—melanoma	2.17e-06	1.26e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GNAQ—melanoma	2.17e-06	1.25e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CD44—melanoma	2.17e-06	1.25e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—AKT1—melanoma	2.15e-06	1.24e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CTNNB1—melanoma	2.15e-06	1.24e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—melanoma	2.15e-06	1.24e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—melanoma	2.14e-06	1.23e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STAT3—melanoma	2.12e-06	1.22e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NRAS—melanoma	2.11e-06	1.22e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—melanoma	2.11e-06	1.22e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1A—melanoma	2.1e-06	1.21e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—melanoma	2.1e-06	1.21e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—melanoma	2.09e-06	1.21e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NFKB1—melanoma	2.09e-06	1.21e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—melanoma	2.08e-06	1.2e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1B1—melanoma	2.08e-06	1.2e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CD—melanoma	2.02e-06	1.17e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK3—melanoma	2.02e-06	1.17e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CD—melanoma	2.01e-06	1.16e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CG—melanoma	2e-06	1.16e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—melanoma	2e-06	1.16e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALB—melanoma	2e-06	1.15e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—melanoma	1.99e-06	1.15e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CA—melanoma	1.97e-06	1.14e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—melanoma	1.97e-06	1.14e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARG—melanoma	1.93e-06	1.12e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK1—melanoma	1.92e-06	1.11e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—melanoma	1.92e-06	1.11e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—melanoma	1.91e-06	1.1e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—melanoma	1.89e-06	1.09e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STAT3—melanoma	1.88e-06	1.08e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NRAS—melanoma	1.87e-06	1.08e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—AKT1—melanoma	1.86e-06	1.07e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AKT1—melanoma	1.84e-06	1.07e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AKT1—melanoma	1.84e-06	1.06e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—melanoma	1.83e-06	1.06e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—melanoma	1.82e-06	1.05e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK3—melanoma	1.79e-06	1.04e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AKT1—melanoma	1.79e-06	1.03e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CB—melanoma	1.76e-06	1.02e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CD—melanoma	1.76e-06	1.02e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CB—melanoma	1.75e-06	1.01e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—melanoma	1.75e-06	1.01e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—melanoma	1.75e-06	1.01e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—melanoma	1.74e-06	1.01e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALB—melanoma	1.74e-06	1.01e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—melanoma	1.74e-06	1e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ABCB1—melanoma	1.71e-06	9.9e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK1—melanoma	1.7e-06	9.85e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—melanoma	1.7e-06	9.85e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CA—melanoma	1.67e-06	9.64e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—melanoma	1.61e-06	9.33e-06	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT1—melanoma	1.61e-06	9.32e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—melanoma	1.61e-06	9.31e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PRKCA—melanoma	1.58e-06	9.11e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ERCC2—melanoma	1.56e-06	9.04e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—melanoma	1.54e-06	8.92e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CB—melanoma	1.54e-06	8.88e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—melanoma	1.52e-06	8.8e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—melanoma	1.52e-06	8.79e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—melanoma	1.51e-06	8.75e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CA—melanoma	1.48e-06	8.55e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—melanoma	1.48e-06	8.54e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—melanoma	1.43e-06	8.27e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—melanoma	1.37e-06	7.91e-06	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT1—melanoma	1.36e-06	7.88e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—melanoma	1.33e-06	7.67e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—melanoma	1.31e-06	7.57e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CG—melanoma	1.23e-06	7.14e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT1—melanoma	1.21e-06	6.99e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARG—melanoma	1.19e-06	6.89e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CD—melanoma	1.09e-06	6.27e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CA—melanoma	1.07e-06	6.21e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALB—melanoma	1.07e-06	6.19e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CA—melanoma	1.07e-06	6.18e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CB—melanoma	9.46e-07	5.47e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—melanoma	9.37e-07	5.42e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CA—melanoma	9.36e-07	5.41e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKT1—melanoma	8.78e-07	5.07e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKT1—melanoma	8.73e-07	5.04e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—melanoma	8.17e-07	4.73e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKT1—melanoma	7.65e-07	4.42e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CA—melanoma	5.77e-07	3.33e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKT1—melanoma	4.71e-07	2.72e-06	CbGpPWpGaD
